FOXO3

FOXO3's Mechanistic Heart — The SRF Enhancer Variant

FOXO3 is the most consistently replicated human longevity gene, with associations validated across
every major population group. While multiple intronic variants in FOXO3 tag longevity haplotypes,
most are statistical proxies — markers in linkage disequilibrium with the true functional variant.
rs4946935 is different: it is one of only two FOXO3 variants with direct experimental proof of
allele-specific function, making it the mechanistic anchor of the largest FOXO3 longevity haplotype.

Flachsbart et al. 2017 | Identification and characterization of two functional variants in the human
longevity gene FOXO3. Nat Commun. 2017 resequenced the
entire FOXO3 locus and genotyped 3,476 long-lived individuals and controls across German, French, and
Danish cohorts. From 122 candidate variants, two emerged with both strong association signals and
functional evidence: rs12206094 and rs4946935. Of the two, rs4946935 carried the lowest p-value in
the combined meta-analysis (OR = 1.19, p = 2.38×10⁻⁵), and was subsequently confirmed as the
lead SNP in the largest four-cohort centenarian study conducted to date.

The Mechanism

rs4946935 sits in intron 3 of FOXO3 at chromosomal position 108,679,539 (GRCh38, chromosome 6).
The G→A transition creates a de-novo binding site for serum response factor (SRF) | a transcription
factor in the MAPK/ERK pathway that responds to growth factor signaling and extracellular stress.
Critically, SRF is not constitutively active at this site — its binding and the enhancer activity
it drives are specifically and substantially suppressed by IGF-1 treatment in reporter assays.

This IGF-1 reversibility connects rs4946935 directly to the insulin/IGF-1 signaling (IIS) pathway —
the most deeply conserved longevity pathway in biology, from yeast and worms to mice and humans.
When circulating IGF-1 is high (as during high-protein feeding, rapid growth, or insulin resistance),
IIS suppresses FOXO3 through AKT-mediated phosphorylation and cytoplasmic sequestration — and the
same signaling environment also suppresses the rs4946935 SRF enhancer. When IGF-1 is low (fasting,
caloric restriction, plant-protein predominance), both the SRF enhancer and FOXO3 nuclear activity
are released simultaneously, compounding the longevity signal.

The rs4946935 haplotype is structurally and mechanistically distinct from the other major FOXO3
longevity locus at rs2802292, which operates through HSF1 (heat shock factor 1) | a stress-response
transcription factor activated by heat, oxidative damage, and proteotoxic stress.
HSF1 responds to cellular damage stress; SRF responds to nutrient and growth factor status. They
are independent FOXO3 regulatory switches — additive in effect, complementary in stimulus.

In line with the enhancer model, eQTL analyses confirm that the A allele of rs4946935 is associated
with higher FOXO3 mRNA expression across multiple human tissues. The A allele is also in strong
linkage disequilibrium (r²=0.96) with rs1935949, another shipped FOXO3 longevity variant — the
two variants tag the same regulatory haplotype and report concordant results in virtually all
genome data.

The Evidence

The primary evidence comes from three layers: functional assays, European cohort replication, and
cross-population meta-analysis.

Functional validation: Flachsbart et al. 2017
confirmed SRF binding to the A allele by electrophoretic mobility shift assay (EMSA), then
demonstrated allele-specific enhancer activity in luciferase reporter assays. Critically, adding
IGF-1 to the culture medium significantly reduced reporter activity in cells with the longevity
A allele, confirming that the enhancer is responsive to the same IIS pathway that regulates FOXO3
protein localization. This dual convergence — both the enhancer and the protein — on the same
nutrient-sensing pathway is a striking mechanistic coherence.

Cohort replication: The German discovery cohort (1,109 LLI ≥95 years including 594 centenarians,
918 controls aged 60–75) showed OR = 1.35 for centenarians (p = 0.0003). This replicated in a
French cohort (1,264 LLI aged 91–115 years, 1,830 controls) at OR = 1.14, p = 0.022, and trended
in the same direction in a Danish cohort (643 LLI, 746 controls, OR = 1.14, p = 0.127).

Cross-population meta-analysis: Bae et al. 2018 | Effects of FOXO3 Polymorphisms on Survival
to Extreme Longevity in Four Centenarian Studies. J Gerontol A Biol Sci Med Sci.
2018 pooled data from the Long Life Family Study,
New England Centenarian Study, Southern Italian Centenarian Study, and Longevity Genes Project —
2,072 cases and 6,194 controls. rs4946935 emerged as the SNP with the lowest p-value across all
FOXO3 variants tested (OR = 1.20, p = 3.20×10⁻⁵). The A allele was enriched in long-lived
individuals in all four cohorts.

Important nuance: The Bae 2018 analysis also examined whether rs4946935 predicts survival to
the most extreme ages (beyond the 1st percentile for the 1900 birth cohort). The survival advantage
was statistically significant for reaching very old age (~90–99 range) but not for survival past
that threshold specifically — suggesting this variant helps people reach advanced old age, but
centenarian status at the extreme tail reflects additional factors.

Practical Implications

The IGF-1 responsiveness of this SRF enhancer is the clearest dietary signal in the FOXO3 longevity
genetics literature. Interventions that lower circulating IGF-1 specifically activate this regulatory
mechanism. The most evidence-based dietary approach is a shift toward plant protein: animal protein
(especially dairy and red meat) is the strongest macronutrient driver of circulating IGF-1; plant
proteins (legumes, tofu, nuts) produce substantially lower IGF-1 responses. Controlled feeding
studies show serum IGF-1 can fall 15–25% within weeks of shifting to predominantly plant protein
while maintaining adequate total protein intake.

Time-restricted eating and periodic fasting also lower IGF-1 acutely and chronically, providing
additional windows during which the SRF enhancer at rs4946935 is maximally active. These
interventions are complementary to the exercise-based HSF1 activation that benefits the rs2802292
longevity locus — carriers of protective alleles at both sites can stack both dietary (IIS reduction)
and stress-response (hormetic exercise) strategies.

The A allele frequency of ~30% in Europeans means the majority of people of European descent carry
at least one copy (AG ~42%, AA ~9%). This is not a rare variant — it is a common regulatory
polymorphism with replicated functional evidence, placing it among the most actionable findings
in longevity genetics.

Interactions

rs4946935 and rs1935949 are in near-perfect LD (r²=0.96) and tag the same regulatory haplotype.
Individuals with genome data from chips that captured one but not the other will receive equivalent
information from either variant. The SRF enhancer mechanism described above applies to both as
proxies of the same functional allele.

rs4946935 and rs2802292 are in different haplotype blocks and respond to different cellular signals:
the SRF enhancer at rs4946935 responds to nutrient status (low IGF-1 during fasting or plant-protein
diet), while the HSF1 enhancer at rs2802292 responds to cellular stress (heat, oxidative damage,
proteotoxic stress). Carriers of protective alleles at both sites activate FOXO3 through two
independent mechanisms, suggesting additive longevity benefit that targets different lifestyle
interventions simultaneously.

rs12206094 is the second independently validated functional FOXO3 variant from the Flachsbart 2017
study. It involves CTCF binding rather than SRF, placing it in a distinct regulatory context.
The combined genotype OR for carrying longevity alleles at both rs12206094 and rs4946935
substantially exceeds either alone.